Watson Pharmaceuticals, Inc. (WPI) announced an exclusive licensing agreement with HRA Pharma for Watson to become the commercial partner for ulipristal acetate, or UPA, a selective progesterone receptor modulator in the U.S. UPA is a novel next-generation emergency contraceptive developed by HRA Pharma specifically for emergency contraceptive use that is approved and marketed by HRA Pharma in Europe as ellaOne since October 2009. UPA is at the New Drug Application stage in the U.S.
As per the terms of the licensing agreement, Watson will make payments to HRA Pharma, based on the achievement of certain milestones. In addition, Watson will also pay HRA Pharma a royalty on U.S. sales of the product. Moreover, Watson will be responsible for all U.S. commercialization and marketing expenses.
For comments and feedback: editorial@rttnews.com